{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:53Z","timestamp":1779196313171,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"\n Introduction<\/jats:title>\n Both chronic lymphocytic leukemia (CLL) itself and the drugs used for its treatment, pose a risk for progressive multifocal leukoencephalopathy (PML). Although the relationship between Rituximab and PML is well known, case reports that have been recently published, suggest that ibrutinib; which is used in the treatment of CLL, may increase the risk of PML.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n Here, we report a case of 64 year-old female patient with CLL who was previously treated with rituximab, fludarabine and bendamustin but developed PML after receiving monotherapy with ibrutinib. According to Naranjo\u2019s algorithm, the causality relationship with the drug is possible with a score of 3. The patient initially exhibited neurological symptoms. Magnetic resonance of the brain revealed a bilateral asymmetric hyperintensity in the white matter involving the parietal and occipital lobules, and there was no mass effect, edema, hemorrhagic or iscemic lesions. No enhancement of contrast media was observed. The findings were consistent with demyelination and suggestive of PML.<\/jats:p>\n <\/jats:sec>\n \n Management and outcome<\/jats:title>\n Mirtazapine treatment was initiated. However, neurological sympthoms continuously progressed over the following weeks and the patient, aged 64, died six weeks after diagnosis of PML.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n PML is a rare and often fatal demyelinating disease of the central nervous system (CNS) that is exclusively seen in immunocompromised patients and there is no specific agent to treat PML. The case discussed here, highlights that the use of ibrutinib in chronic lymphocytic leukemia (CLL) therapy may result in PML.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552221074281","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:10:55Z","timestamp":1642417855000},"page":"1249-1253","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-235X","authenticated-orcid":false,"given":"Tu\u011fba","family":"\u00c7etintepe","sequence":"first","affiliation":[{"name":"Izmir Katip Celebi University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00fcsun","family":"Gediz","sequence":"additional","affiliation":[{"name":"Medical Park Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u015f\u0131n","family":"Akyar","sequence":"additional","affiliation":[{"name":"Acibadem University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutfi","family":"\u00c7etintepe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Celal Bayar, Manisa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Murat","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Izmir Bozyaka Education and Research Hospital Izmir"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.12.013"},{"key":"e_1_3_2_3_2","first-page":"1257","article-title":"Cultivation ofpapova-like virus from human brain with progressive multifocal leucoencephalopathy","volume":"1","author":"Padgett BL","unstructured":"Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation ofpapova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971 Jun 19; 1: 1257\u20131260.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphaticleukaemia and Hodgkin's Disease","volume":"81","author":"Astrom KE","unstructured":"Astrom KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphaticleukaemia and Hodgkin's Disease. Brain 1958 Mar; 81: 93\u2013111.","journal-title":"Brain"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-3-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00282-999-0183-7"},{"key":"e_1_3_2_7_2","first-page":"4247","article-title":"Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature","volume":"60","author":"Di Pauli F","unstructured":"Di Pauli F, Berger T, Walder A, et al. Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature. J ClinVirol 2014 Aug; 60: 4247.","journal-title":"J ClinVirol"},{"key":"e_1_3_2_8_2","first-page":"239","article-title":"A. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocyticleukemia patient","volume":"33","author":"Lejniece S","unstructured":"Lejniece S, Murovska M, Chapenko S, et al. A. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocyticleukemia patient. Exp Oncol 2011 Dec; 33: 239\u2013241.","journal-title":"Exp Oncol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.110"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14322"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1198775"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.1.49"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05031-11"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0003-4"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136556"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221074281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:23Z","timestamp":1779194243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221074281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552221074281"],"URL":"https:\/\/doi.org\/10.1177\/10781552221074281","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}